4.6 Review

Genetically-defined metabolic reprogramming in cancer

Journal

TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 23, Issue 11, Pages 552-559

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2012.06.009

Keywords

-

Funding

  1. National Institutes of Health (NIH) [5T32GM083831, CA157996]
  2. Cancer Prevention and Research Institute of Texas [HIRP100437, RP101243]
  3. Robert A. Welch Foundation [I-1733]
  4. Damon-Runyon Cancer Research Foundation

Ask authors/readers for more resources

Oncogenes and tumor suppressors regulate cell metabolism. Evidence demonstrates that tumorigenic mutations in these genes tend to orchestrate metabolic activity into a platform that promotes cell survival, growth, and proliferation. Recent work has shown that some metabolic enzymes are also mutated in cancer, and that these mutations may influence malignancy directly. Thus, these enzymes seem to function as oncogenes and tumor suppressors, and would appear to be compelling targets for therapeutic intervention. Here, we review several enzymes mutated in cancer - phosphoglycerate dehydrogenase, isocitrate dehydrogenases 1 and 2, succinate dehydrogenase, and fumarate hydratase - and discuss exciting new work that has begun to pull back the curtain on how mutations in these enzymes influence tumorigenesis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available